Media coverage about Myovant Sciences (NYSE:MYOV) has been trending somewhat positive recently, Accern Sentiment reports. The research firm rates the sentiment of media coverage by reviewing more than twenty million blog and news sources. Accern ranks coverage of companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Myovant Sciences earned a media sentiment score of 0.21 on Accern’s scale. Accern also assigned media headlines about the company an impact score of 45.4640501524351 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the stock’s share price in the immediate future.
Several brokerages have commented on MYOV. JMP Securities reaffirmed an “outperform” rating and set a $25.00 target price (up from $23.00) on shares of Myovant Sciences in a report on Wednesday, October 4th. Robert W. Baird reissued a “buy” rating and issued a $20.00 price objective on shares of Myovant Sciences in a research note on Wednesday, October 4th. Cowen and Company reissued a “buy” rating on shares of Myovant Sciences in a research note on Tuesday, October 3rd. Zacks Investment Research raised Myovant Sciences from a “sell” rating to a “hold” rating in a research note on Friday, August 25th. Finally, Evercore ISI started coverage on Myovant Sciences in a research note on Wednesday, August 16th. They issued an “outperform” rating on the stock. One research analyst has rated the stock with a sell rating and six have assigned a buy rating to the company. The stock has a consensus rating of “Buy” and an average price target of $20.00.
Myovant Sciences (MYOV) traded down $0.43 during mid-day trading on Friday, reaching $12.96. The company had a trading volume of 24,673 shares, compared to its average volume of 33,380. Myovant Sciences has a fifty-two week low of $9.92 and a fifty-two week high of $18.85.
TRADEMARK VIOLATION WARNING: This piece of content was first posted by TrueBlueTribune and is owned by of TrueBlueTribune. If you are accessing this piece of content on another site, it was illegally copied and reposted in violation of U.S. and international trademark and copyright legislation. The correct version of this piece of content can be accessed at https://www.truebluetribune.com/2017/11/18/somewhat-positive-media-coverage-somewhat-unlikely-to-impact-myovant-sciences-myov-stock-price.html.
About Myovant Sciences
Myovant Sciences Ltd. is a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for women’s health diseases and other endocrine-related disorders. Its main product candidate is Relugolix. Relugolix is an oral, once-daily, small molecule that acts as a gonadotropin-releasing hormone (GnRH) receptor antagonist that binds to and inhibits receptors in the anterior pituitary gland.
Receive News & Ratings for Myovant Sciences Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Myovant Sciences Ltd. and related companies with MarketBeat.com's FREE daily email newsletter.